Condition: Hospital-acquired Bacterial Pneumonia · Ventilator-associated Bacterial Pneumonia · Sponsor: Omnix Medical Ltd
This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.
This description comes directly from the study's public registry record.
Bella Shusterman · +972 2 5320871 · bella@omnixmedical.com
Always discuss trial participation with your own doctor first.
| Omnix Medical Research Site | Ashdod, Israel | Recruiting |
| Omnix Medical Research Site | Be’er Ya‘aqov, Israel | Recruiting |
| Omnix Medical Research Site | Holon, Israel | Recruiting |
| Omnix Medical Research Site | Petah Tikva, Israel | Recruiting |
| Omnix Medical Research Site | Ramat Gan, Israel | Recruiting |
| Omnix Medical Research Site | Rishon LeZiyyon, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06087536